Table 5.
Time to first ARIA-E event and time to ARIA-E resolution by APOE ɛ4 carrier status
| APOE ɛ4 carrier status | |||||
| 1ɛ4 (n = 100) | 2ɛ4 (n = 38) | Carriers (n = 138) | Noncarriers (n = 81) | Total (N = 219) | |
| Time to first ARIA-E event | |||||
| n | 28 | 23 | 51 | 19 | 70 |
| Mean, weeks (SD) | 25.12 (11.08) | 20.22 (10.15) | 22.91 (10.85) | 21.68 (11.02) | 22.58 (10.83) |
| Median, weeks | 24.29 | 15.29 | 21.14 | 18.43 | 19.43 |
| Q1–Q3, weeks | 14.79–33.93 | 13.29–26.00 | 13.71–32.14 | 14.29–25.71 | 14.00–26.14 |
| Min–Max, weeks | 10.0–45.3 | 5.1–48.3 | 5.1–48.3 | 5.1–46.3 | 5.1–48.3 |
| Time to ARIA-E resolution | |||||
| Duration of all resolved ARIA-E events | |||||
| n | 25 | 22 | 47 | 15 | 62 |
| Mean, weeks (SD) | 19.26 (13.91) | 16.95 (11.24) | 18.18 (12.65) | 19.92 (19.27) | 18.60 (14.37) |
| Median, weeks | 16.29 | 14.93 | 15.43 | 13.14 | 15.36 |
| Q1–Q3, weeks | 8.71–22.57 | 8.29–22.71 | 8.29–22.71 | 8.00–20.71 | 8.14–22.57 |
| Min-Max, weeks | 3.3–61.4 | 3.3–46.7 | 3.3–61.4 | 4.9–74.4 | 3.3–74.4 |
| Duration of all unresolved ARIA-E events | |||||
| n | 4 | 2 | 6 | 4 | 10 |
| Mean, weeks (SD) | 51.07 (53.54) | 30.43 (8.08) | 44.19 (42.97) | 25.46 (26.82) | 36.70 (36.87) |
| Median, weeks | 34.93 | 30.43 | 33.64 | 17.86 | 29.93 |
| Q1–Q3, weeks | 18.50–83.64 | 24.71–36.14 | 24.71–38.71 | 5.50–45.43 | 7.00–38.71 |
| Min–Max, weeks | 5.9–128.6 | 24.7–36.1 | 5.9–128.6 | 4.0–62.1 | 4.0–128.6 |
APOE ɛ4, apolipoprotein E ɛ4 allele; ARIA-E, amyloid-related imaging abnormalities-edema; Q1, first quartile 1; Q3, third quartile; SD, standard deviation.